Pre-made Larcaviximab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-297

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-297 Category Tag

Product Details

Pre-Made Larcaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Larcaviximab is a chimeric (mouse/human) monoclonal antibody that can be potentially used in the treatment of Ebola Virus Infection.

Products Name (INN Index)

Pre-Made Larcaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody

INN Name

Larcaviximab

Target

Zaire Ebolavirus GP

Format

Whole mAb

Derivation

Chimeric (Mouse/Human)

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

5ken:CD:GH:NO

95-98% SI Structure

None

Year Proposed

2016

Companies

Mapp Biopharmaceutical,Public Health Agency of Canada,National Institute of Allergy and Infectious Diseases

Conditions Approved

NA

Conditions Active

Ebola virus infections

Conditions Discontinued

NA

Development Tech

Zmapp Technology

Previous Name

NA

Gm Offical Target Name

Zaire Ebolavirus GP

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide